ArticleArchives of dermatological research2025
The cardiometabolic safety of dupilumab in atopic dermatitis: A global large-scale cohort study.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review.Cureus · 2026Review
- Skin Care Supports Overall Well-Being.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA low risk of cardiovascular and metabolic outcomes was found in the randomized clinical trials of dupilumab in atopic dermatitis (AD). Dupilumab-associated real-life long-term cardiometabolic risk relative to other systemic agents is yet to be precisely investigated.
objectiveTo assess the risk of cardiometabolic outcomes in patients with AD treated with dupilumab relative to those treated with methotrexate and cyclosporine.
methodsA global retrospective cohort study comprised two distinct analyses comparing patients with AD under different treatments: (i) initiators of dupilumab (n = 10,151) versus methotrexate (n = 10,151) and (ii) initiators of dupilumab (n = 6,629) versus TNFi (n = 6,629). Study groups were compared regarding the risk of 8 cardiovascular and 4 metabolic outcomes during the initial three years following drug initiation. Propensity score matching was conducted to optimize inter-group comparability.
resultsCompared to methotrexate, dupilumab was associated with a decreased risk of peripheral vascular disease (PVD; hazard ratio [HR], 0.64; 95% confidence interval CI 0.45-0.90; P = 0.011), deep vein thrombosis (DVT; HR, 0.42; 95% CI, 0.26-0.69; P < 0.001), hypertension (HR, 0.67; 95% CI, 0.58-0.79; P < 0.001), type-2 diabetes mellitus (T2DM; HR, 0.53; 95% CI, 0.42-0.68; P < 0.001), and obesity (HR, 0.70; 95% CI, 0.58-0.86; P = 0.001) within the first year of treatment. Relative to cyclosporine, dupilumab conferred a lower risk of hypertension (HR, 0.52; 95% CI, 0.45-0.62; P < 0.001), hyperlipidemia (HR, 0.59; 95% CI, 0.49-0.71; P < 0.001), and T2DM (HR, 0.62; 95% CI, 0.48-0.81; P < 0.001),
conclusionDupilumab possesses a favorable cardiometabolic safety profile and might be preferred in patients with susceptibility and risk factors of these conditions.
Indexed as
Identifiers
39833567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.